Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Head of the Medical Sciences Division and the Dean of the Medical School, Professor Alastair Buchan has been elected as an Honorary Member in the American Neurological Association (ANA).

Honorary membership is the highest honour that the ANA bestows and is reserved for individuals who have made unique contributions to neurology and neurological sciences.  Professor Buchan will be presented his membership at the ANA Annual Meeting in New Orleans later today.

Since 1986, Professor Buchan has practiced as a neurologist and neuroscientist in Stroke Medicine. He is currently Professor of Stroke Medicine in the Radcliffe Department of Medicine of the John Radcliffe Hospital where he is also an Honorary Consultant Neurologist.  He is a Professorial Fellow at Corpus Christi College, Oxford.

Professor Buchan was educated at Repton School, studied at Cambridge, Oxford, and Harvard and undertook Medicine and Neurology Specialty training at Oxford and Imperial. He completed the Neurology Residency Training Program in London, Ontario, Canada and specialty training as a Clinical Fellow at Cornell University Medical College in New York.  His research interests are in neuroprotection following ischemia and his clinical research is in intervention, thrombolysis, and neuroprotection in acute stroke. 

He led the Calgary Stroke Program at Foothills Hospital and was Heart and Stroke Foundation Professor of Stroke Research at the University of Calgary from 1995 to 2005.  His team pioneered the introduction of thrombolysis in a community setting which led to both the Canadian CASES and FASTER studies.

Among his many notable achievements, Professor Buchan established the Acute Stroke Programme, led the Oxford Clinical Research Facility and the new Acute Vascular Imaging Centre, and was the founding Director of the Oxford NIHR Biomedical Research Centre. He became Head of the Medical Sciences Division of the University of Oxford on October 1 2008 and Dean of the Oxford Medical School in 2007.  The medical school has held the top rank worldwide in Clinical, Pre-clinical and Health since 2011, in the Times Higher Education subject rankings.

Professor Buchan has made several significant contributions to cerebrovascular disease. His clinical interests remain in acute stroke and stroke prevention and the opportunity to derive large data sets with respect to clinical trials in thrombolysis and neuroprotection and the stratification of these patients through quantitative image analysis, such as the ASPECTS score.  His basic research into mechanisms of cell death following cerebral ischemia has recently resulted in a new finding, which suggests that the tuberose sclerosis (TSC 1) gene product Hamartin confers neuroprotection against ischemia by introducing autophagy.

On hearing the news, Professor Buchan said: “I am both delighted and honoured to receive Honorary Membership from the American Neurological Association, the world’s leading institution of neurologists, many of whom have been my mentors and leaders since my early training at Cornell."

Links:

Professor Buchan’s webpage
Professor Buchan's departmental webpage
American Neurological Association

Similar stories

MRC HIU appoints new Director

Awards and Appointments General

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

New Year's Honours 2021

Awards and Appointments General

Members of the Medical Sciences Division have been recognised in the New Year's Honours list for 2021.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards and Appointments General

Oxford University has been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

Awards and Appointments General

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards and Appointments General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced today*. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.